# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Douglas Tsao maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price t...
Oppenheimer analyst Leland Gershell maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price tar...
Ladenburg Thalmann analyst Michael Higgins downgrades Viridian Therapeutics (NASDAQ:VRDN) from Buy to Neutral.
B. Riley Securities analyst Kalpit Patel downgrades Viridian Therapeutics (NASDAQ:VRDN) from Buy to Neutral and lowers the p...
Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $30 price target.
Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of...
B. Riley Securities analyst Kalpit Patel maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price targe...
Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $30 price target.